tbuckley/cabot-search huggingface dataset:
Multiple Arterial Occlusions
Authors: Harold W. Dana
Journal: Annals of Internal Medicine (1932)

Article1 February 1932Multiple Arterial OcclusionsHAROLD W. DANA, M.D., F.A.C.P.HAROLD W. DANA, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-5-8-955 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFor many years we have been cautioned, with regard to the use of quinidine in the treatment of auricular fibrillation, of the possible danger that we might cause the extrusion into the circulation, when the previously dilated auricles should contract, of thrombi formed in these inactive chambers of the heart. Such an accident would seem not only to be possible, but even to be likely, should any method of treatment be successful in re-establishing rhythmic contraction of auricles long inactive, and undoubtedly this misfortune does at times follow the use of this drug, although much less frequently than one would...References1 MACKENZIE J: Diseases of the heart, 1914, H. Frowde, London, 379, 235. Google Scholar2 HARE HA: A therapeutic referendum, 1928, Prog. Med., iv, 311-417. Google Scholar3 MEYERS SG: Emptying of the gall bladder with especial reference to the use of pituitrin, Am. Jr. Med. Sci., 1928, clxxv, 405-410. CrossrefGoogle Scholar4 SCHONDUBE W: Röntgenologische Beiträge zum Entleerungsmechanismus der Gallenblase, Fortschr. a. d. Geb. d. Röntgenstrahlen, 1927, xxxvi, 603-609. Google Scholar5 DALE HH: The action of extracts of the pituitary body, Biochem. Jr., 1909, iv, 427-446. CrossrefGoogle Scholar6 WIGGERS CJ: The physiology of the pituitary gland and the actions of its extracts, Am. Jr. Med. Sci., 1911, cxli, 502-515. CrossrefGoogle Scholar7 ROSSDREYERSTEHLE JBNBRL: Cardiac action of pituitary extract, Jr. Pharm. and Exper. Therap., 1930, xxxviii, 451-460. Google Scholar8 KOLLSGEILING ACEM: Pharmacology of extracts of posterior lobe of pituitary gland, Jr. Pharm. and Exper. Therap., 1924, xxiv, 67-81. Google Scholar9 GEILINGRESNIK EMWH: Action of pituitary tartrate on heart of unanesthetized dog, Jr. Clin. Invest. 1925, i, 239-245. CrossrefGoogle Scholar10 HALSEY JT: Organotherapy and hormotherapy, Endocrinology and Metabolism (Barker, L. F.), 1922, i, Sec. i, D. Appleton and Company, New York, 114-115. Google Scholar11 GEILINGRESNIK EMWH: Action of pituitary extract on the heart of unanesthetized dog, Jr. Clin. Invest., 1925, i, 217-238. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Mass.*Submitted for publication, June 9, 1931. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1932Volume 5, Issue 8Page: 955-961KeywordsAtrial fibrillationDrugsHeart ePublished: 1 December 2008 Issue Published: 1 February 1932 PDF downloadLoading ...
DIPHTHERIA CARRIERS TREATED WITH PENICILLIN
Authors: Rudolph A. Kocher, Walter J. Siemsen
Journal: Annals of Internal Medicine (1946)

Article1 May 1946DIPHTHERIA CARRIERS TREATED WITH PENICILLINRUDOLPH A. KOCHER, WALTER J. SIEMSENRUDOLPH A. KOCHERSearch for more papers by this author, WALTER J. SIEMSENSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-24-5-883 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe majority of patients with diphtheria rid themselves of bacilli within the first two weeks after recovery. However, there remains a fairly large percentage of cases who become carriers and who present a serious danger to the spread of the disease unless isolated or freed of the infecting organism. Heretofore, although a great variety of bactericidal agents has been tried, the treatment of carriers has remained unsatisfactory.It has previously been shown by Abraham, Chain, et al.1Chain, Florey et al.,2and by Fleming,3thatCorynebacterium diphtheriaeis susceptible to the action of penicillin in vitro. Because of this fact...Bibliography1. ABRAHAMCHAINFLETCHERFLOREYGARDNERHEATLEYJENNINGS EPECMHWADNGMA: Further observations on penicillin, Lancet, 1941, ii, 177-188. CrossrefGoogle Scholar2. CHAINFLOREYGARDNERHEATLEYJENNINGORR-EWINGSANDERS EHWADNGMAJAG: Penicillin as a chemotherapeutic agent, Lancet, 1940, ii, 226-228. CrossrefGoogle Scholar3. FLEMING A: A simple method of using penicillin, tellurite and gentian violet for differential culture, Brit. Med. Jr., 1942, i, 547-548. CrossrefGoogle Scholar4. WRIGHT HA: Laboratory diagnosis of diphtheria; note on some present-day methods, Edinburgh Med. Jr., 1943, l, 787. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication August 10, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie DiphtherieDie DiphtherieThis Month in MedicineThis Month in Medicine 1 May 1946Volume 24, Issue 5Page: 883-886KeywordsDiphtheriaInfectious diseasesPenicillin ePublished: 1 December 2008 Issue Published: 1 May 1946 PDF downloadLoading ...
POSSIBILITIES IN BIOLOGICAL ENGINEERING
Authors: Karl T. Compton
Journal: Annals of Internal Medicine (1938)

Article1 December 1938POSSIBILITIES IN BIOLOGICAL ENGINEERINGKARL T. COMPTONKARL T. COMPTONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-6-867 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen I asked myself why I, a physicist, should be invited to address you, America's most distinguished body of physicians, I found an answer extending back over many centuries. For physics and medicine have been closely associated from their very beginnings. The words physics and physician both derive from the Greek root meaning "that which pertains to nature" as distinguished from the spiritual, mental and moral world. Webster's Dictionary gives two definitions of "physicist": first, one versed in medical science; second, one versed in natural science. In France I, as a physicist, would be called a physicien. In Germany I... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cambridge, Massachusetts*Convocation Address, Twenty-Second Annual Session, American College of Physicians, New York, April 6, 1938, by Karl T. Compton, President, Massachusetts Institute of Technology. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1938Volume 12, Issue 6Page: 867-875KeywordsPhysicists ePublished: 1 December 2008 Issue Published: 1 December 1938 PDF downloadLoading ...
Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220
Authors: Christoph Schaab, Felix Oppermann, Heike Pfeifer, Martin Klammer, Andreas Tebbe, Thomas Oellerich, Jürgen Krauter, Mark J. Levis, Alexander E Perl, Henrik Daub, Björn Steffen, Klaus Godl, Hubert Serve
Journal: Blood (2012)
ANAPHYLACTOID REACTION FOLLOWING ADMINISTRATION OF ONE MEPROBAMATE TABLET
Authors: David M. Nevins
Journal: Annals of Internal Medicine (1960)

Case Reports1 July 1960ANAPHYLACTOID REACTION FOLLOWING ADMINISTRATION OF ONE MEPROBAMATE TABLETDAVID M. NEVINSDAVID M. NEVINSSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-53-1-192 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBecause of the countless number of drugs in use these days, we can expect more and more reports of bizarre side-effects, some quite serious and even life-threatening. The case that follows illustrates this point. The medication involved here is meprobamate,† a tranquilizer widely used and apparently relatively safe. Numerous minor reactions have been reported with meprobamate, but most of these were due to overdosage. Only a few cases have been recorded of hypotensive episodes following the administration of this drug.CASE REPORTA 35 year old white male was admitted by ambulance to Lockbourne Air Force Base Hospital around 8:30...Bibliography1. ScottGrimshawMalony PALHM: Hypotensive episodes following treatment with meprobamate, Lancet 2: 1158-1159, 1956. CrossrefGoogle Scholar2. Selling LS: Clinical study of a new tranquilizing drug: use of Miltown, J. A. M. A. 157: 1594-1596, 1955. CrossrefMedlineGoogle Scholar3. Charkes DN: Meprobamate idiosyncrasy, Arch. Int. Med. 102: 584-593, 1958. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: USAF (MC) Columbus, Ohio*Received for publication April 1, 1960.†Meprobamate—Miltown (Wallace Laboratories, New Brunswick, New Jersey).Requests for reprints should be addressed to David M. Nevins, Captain, USAF (MC), 15 B Buckeye Circle, Lockbourne Air Force Base, Columbus, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byANAPHYLACTIC REACTIONS FROM SHELLFISHTHE HISTOPATHOLOGY OF DRUG-INDUCED LIVER DISEASEAcidic and Neutral PoisonsAnaphylaxisShock in infectious diseases 1 July 1960Volume 53, Issue 1Page: 192-193KeywordsAmbulancesDrug administrationDrugsHypotensive episodesIngestionPharmacodynamics ePublished: 1 December 2008 Issue Published: 1 July 1960 PDF downloadLoading ...
Cyclophosphamide Followed By Busulphan in Place of Standard BuCy Regimen for Patients Undergoing Allogeneic Stem Cell Transplantation: A Preliminary Experience from a Single Centre in India
Authors: Sainath Bhethanabhotla, Ranjit Kumar Sahoo, Lalit Kumar, Atul Sharma, Sameer Bakhshi
Journal: Blood (2014)
The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where
Authors: Ioannis S. Pateras, Sophia Havaki, Xenia Nikitopoulou, Konstantinos Vougas, Paul A. Townsend, Michalis I. Panayiotidis, Alexandros G. Georgakilas, Vassilis G. Gorgoulis
Journal: Pharmacology & Therapeutics (2015)
Five-year experience of a community outreach program for the elderly
Authors: B V Reifler, A Kethley, P O'Neill, R Hanley, S Lewis, D Stenchever
Journal: American Journal of Psychiatry (1982)

The authors report on more than 2,000 impaired elderly people who were referred to a geriatric outreach program during its first 5 years of operation. These patients were referred by a wide variety of professionals and private citizens, who were usually concerned about the person's ability to care for himself or herself or about psychiatric symptoms. The most common diagnosis was dementing illness (21% of the patients), followed by depression (13%). Intervention usually involved making appropriate plans based on an accurate diagnosis, often including coordinating the services of other agencies. A follow-up of 100 patients showed that most of the patients who were still living had maintained their independence.
Abstract 17773: Peptide Inhibition of PTEN Increases Mouse Survival after Sudden Cardiac Arrest
Authors: Xiangdong Zhu, Huashan Wang, Youhua Wang, Jing Li, Alan R Leff, Terry L Vanden Hoek
Journal: Circulation (2014)

Introduction: We recently reported that TAT fusion proteins designed to activate versus inhibit the Akt related phosphatase PTEN in heart cells respectively worsen or significantly improve ischemia/reperfusion injury and contractile functional recovery. We therefore designed a short 20 amino acid peptide PTEN inhibitor, TAT-PTEN9c, for rapid tissue delivery and tissue protection after mouse sudden cardiac arrest (SCA). TAT-PTEN9c contains a TAT protein transduction domain fused to the PTEN C-terminal 9 amino acids of the PDZ-domain binding motif. We hypothesized that TAT-PTEN9c blocks PTEN membrane localization and activation, with corresponding tissue Akt activation and improved SCA survival. Methods: Mouse cardiomyocytes were isolated from 1-3 day old mouse pups. Western blot was used to determine the efficacy of TAT-PTEN9c for enhancing Akt phosphorylation in mouse cardiomyocytes exposed to oxidant (H2O2) stress. C57BL6 mice were subjected to an established potassium-induced 8 min SCA protocol. MAP, ETCO2, body temperature and ECG were recorded until 4 h after successful cardiopulmonary resuscitation (CPR). TAT-PTEN9c (7.8 mg/kg) was given intravenously (IV) immediately after CPR (n=10) and a 2nd dose in an additional 5 mice was given at 60 min. IV administration of TAT-GFP was used to measure the kinetics of heart and brain tissue TAT protein delivery. Results: The designed TAT-PTEN9c peptide significantly enhanced Akt activation in neonatal mouse cardiomyoctes in a concentration-dependent manner. 30 mice with successful CPR were randomly assigned to receive either saline or TAT-PTEN9c. Survival (versus cardiovascular collapse and death) was significantly increased in TAT-PTEN9c treated group compared with that of saline control at 2 h (14/15, 93% vs. 9/15, 60%, P &lt; 0.05) and at 4 h (10/15, 67% vs. 6/15, 40%, P &lt; 0.05) after CPR. Western blot and immunohistochemistry showed that TAT protein transduction in heart and brain was diffuse and occurred within 5 min after IV administration. Conclusion: TAT-PTEN9c can be used after CPR in a mouse SCA model to rapidly enhance Akt activation in critical organs and prevent early cardiovascular collapse and death.
Abstract 540: Angiotensin II and Reactive Oxygen Species (ROS) Induce ERK5-SUMOylation and Inhibit ERK5 Transcriptional Activity: Implication in Diabetic Cardiomyopathy (DMC)
Authors: Tetsuro Shishido, Chang-Hoon Woo, Bo Ding, Carolyn McClain, Zhibo lu, Haodong Xu, Chen Yan, Jun-ichi Abe
Journal: Circulation (2006)

BACKGROUND SUMOylation is a novel post translational modification system and affects on protein localization and inhibits transcriptional activities. ERK5 is a member of the MAP kinase family, whic...
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
Authors: R. Phillip Dellinger, Mitchell M. Levy, Jean M. Carlet, Julian Bion, Margaret M. Parker, Roman Jaeschke, Konrad Reinhart, Derek C. Angus, Christian Brun-Buisson, Richard Beale, Thierry Calandra, Jean-Francois Dhainaut, Herwig Gerlach, Maurene Harvey, John J. Marini, John Marshall, Marco Ranieri, Graham Ramsay, Jonathan Sevransky, B. Taylor Thompson, Sean Townsend, Jeffrey S. Vender, Janice L. Zimmerman, Jean-Louis Vincent
Journal: Intensive Care Medicine (2008)
Multiple Primary Melanomas from Same Patients Present Discrepant Somatic Alterations in Main Candidate Genes
Authors: M. Colombino, M. Sini, V. De Giorgi, A. Lissia, D. Massi, C. Rubino, A. Cossu, F. Ayala, P.A. Ascierto, G. Palmieri
Journal: Annals of Oncology (2012)
Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial
Authors: Enrico Tiacci, Luca De Carolis, Pier Luigi Zinzani, Alessandro Pulsoni, Francesco Zaja, Michele Cimminiello, Achille Ambrosetti, Davide Rossi, Giovanna Motta, Marzia Varettoni, Vincenzo Fraticelli, Angelo Michele Carella, Antonella Anastasia, Pietro Leoni, Alessandro Rambaldi, Stefano Aldo Pileri, Robin Foà, Brunangelo Falini
Journal: Blood (2014)
Respective impact of no escalation of treatment, withholding and withdrawal of life-sustaining treatment on ICU patients’ prognosis: a multicenter study of the Outcomerea Research Group
Authors: Alexandre Lautrette, Maïté Garrouste-Orgeas, Pierre-Marie Bertrand, Dany Goldgran-Toledano, Samir Jamali, Virginie Laurent, Laurent Argaud, Carole Schwebel, Bruno Mourvillier, Michaël Darmon, Stéphane Ruckly, Anne-Sylvie Dumenil, Virginie Lemiale, Bertrand Souweine, Jean-François Timsit
Journal: Intensive Care Medicine (2015)
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.
Authors: Sı́lvia Beà, Maria Ribas, Jesús M. Hernández, Francesc Bosch, Magda Pinyol, Luis Hernández, Juan Luis Garcı́a, Teresa Flores, Marcos González, Armando López-Guillermo, Miguel A. Piris, Antonio Cardesa, Emilio Montserrat, Rosa Miró, Elı́as Campo
Journal: Blood (1999)
New Treatment Strategies Provide More Options for Patients With Breast Cancer
Authors: Tracy Hampton
Journal: JAMA (2008)

CHICAGO—Recently completed clinical trials indicate that new treatment strategies may control disease and improve survival for patients with breast cancer, in some cases in advanced disease. The findings, presented here at the annual meeting of the American Society of Clinical Oncology in June, suggest that patients with breast cancer will soon have more options for treating the disease. “We have a multitude of therapies for women with breast cancer but continue to need new treatments that are more effective and have fewer side effects,” said Eric Winer, MD, professor of medicine at Harvard Medical School and director of the Breast Oncology Center at the Dana-Farber Cancer Institute, both in Boston. In 2008, about 182 460 new cases of invasive breast cancer will be diagnosed among women in the United States, according to estimates by the American Cancer Society. An additional 67 770 US women will be diagnosed in 2008 with the earliest, noninvasive form of breast cancer, carcinoma in situ. “Among women who have early stage breast cancer, our goal is to prevent recurrences and ultimately to prevent death from breast cancer while minimizing the side effects from treatment,” Winer said. “And in women with late-stage or metastatic breast cancer . . . our goal is to maintain quality of life, to control the disease, and to extend the period of time that a woman is alive with cancer.” Studies presented at the conference indicate that zoledronic acid can help prevent recurrence in early stage breast cancer, that adding bevacizumab to docetaxel slows disease progression in patients newly diagnosed as having locally advanced or metastatic breast cancer, and that the oral chemotherapy agent capecitabine is not an acceptable replacement for standard adjuvant chemotherapy in older women.
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease
Authors: X Peng, M Dong, L Ma, X-E Jia, J Mao, C Jin, Y Chen, L Gao, X Liu, K Ma, L Wang, T Du, Y Jin, Q Huang, K Li, L I Zon, T Liu, M Deng, Y Zhou, X Xi, Y Zhou, S Chen
Journal: Leukemia (2015)
Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?
Authors: Ben Bailiff, Neil Phillips, Vidhya Murthy, Lynn Bratby, Kathy Holder, Bhuvan Kishore, E Nikolousis, R Lovell, Guy Pratt, Joanne Ewing, Shankaranarayana Paneesha
Journal: Blood (2013)
Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison
Authors: Moshe Yair Levy, Lisa J McGarry, Hui Huang, Stephanie Lustgarten, Christopher Nieset, Frank G Haluska
Journal: Blood (2014)
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
Authors: Jean-Jacques Kiladjian, Florian H Heidel, Alessandro M. Vannucchi, Vincent Ribrag, Francesco Passamonti, Amjad Hayat, Eibhlin Conneally, Bruno Martino, Thomas Kindler, Daniel B. Lipka, Suddhasatta Acharyya, Prashanth Gopalakrishna, Susan E Ide, Sabine Loechner, Song Mu, Claire N Harrison
Journal: Blood (2014)
Coping with winter bed crises
Authors: B. Hanratty, M. Robinson
Journal: BMJ (1999)

Sudden increases in hospital admissions have been a feature of the NHS for many years, but explicit plans for their management were not introduced until 1996, after a particularly severe crisis that January.1 Since then research has been proposed,2 and the emergency services action team has made practical recommendations on such issues as diverting hospital admissions or speeding discharge arrangements.3 This work has concentrated on what to do when winter pressures arise, and this year most hospitals will be better prepared. However, the NHS also needs to be able to anticipate the rise in demand so it can implement plans and notify the public. This issue has received less attention, yet early indicators exist that could be used to warn of impending problems.

Effective forecasting of peaks requires an understanding of their causes and indicators that rise at least a few days before the increase in demand. In two of the past three years peak demand in the NHS coincided with the new year …
O068 : Lysosomal cholesterol in kupffer cells, particularly when oxidized, contributes to murine steatohepatitis
Authors: S. Walenbergh, T. Houben, T. Hendrikx, P. van Gorp, M. Jeurissen, V. Bieghs, M.-H. Lenders, M. Gijbels, J. Plat, M. Hofker, C. Binder, D. Luetjohann, F. Verheyen, G. Koek, R. Shiri-Sverdlov
Journal: Journal of Hepatology (2015)
Unique and Unexpected Functional Activities of Hematopoietically Active Cytokines Truncated By Dipeptidylpeptidase-4 (DPP4)
Authors: Heather A. O'Leary, Charlie Mantel, Man Ryul Lee, Xianyin Lai, Scott Cooper, Giao Hangoc, H. Scott Boswell, Hal E. Broxmeyer
Journal: Blood (2014)
Abstract 6082: Sex Differences in Mortality after Acute Myocardial Infarction: Changes from 1994 to 2006
Authors: Viola Vaccarino, Lori Parsons, Eric D Peterson, William J Rogers, Catarina Kiefe, John Canto
Journal: Circulation (2008)

Introduction. In the past 10 years, several studies have shown that younger, but not older, women have a higher hospital mortality than age-matched men. We examined whether such mortality differences have declined in recent years. Methods. We investigated temporal tends in the case fatality of MI according to sex and age (in 5 age groups) during a12-year period, 1994 to 2006. The study population included 916,380 MI patients from the National Registry of Myocardial Infarction (NRMI) who had a confirmed diagnosis of MI. Results. Hospital mortality declined markedly between 1994 and 2006 in all patients, but more so in women than in men in virtually every age group. The mortality reduction in 2006 relative to 1994 was largest in women &lt;55 years old (53%) and lowest in men &lt;55 years old (33%). In patients &lt;55 years, the absolute decline in mortality was 3 times larger in women than in men (2.7% vs 0.9%). The sex difference in mortality decline became progressively lower in older patients (p=0.002 for the interaction between sex, age and year). As a result, the excess mortality in younger women compared with men was less pronounced in 2004 – 06 than in 1994 –95 (Figure ). Changes in patient characteristics and treatments over time accounted in part for these mortality trends. Conclusion. In recent years, women, particularly younger women, experienced larger improvements in hospital mortality after MI than men. As a result, the higher mortality of younger MI women compared with men has narrowed.